Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 606.00 GBp
Change Today +4.00 / 0.66%
Volume 149.1K
As of 11:35 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

gw pharmaceuticals plc (GWP) Snapshot

Open
610.00 GBp
Previous Close
602.00 GBp
Day High
614.00 GBp
Day Low
604.00 GBp
52 Week High
06/25/15 - 708.00 GBp
52 Week Low
10/16/14 - 299.50 GBp
Market Cap
1.6B
Average Volume 10 Days
249.4K
EPS TTM
-0.07 GBp
Shares Outstanding
261.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GW PHARMACEUTICALS PLC (GWP)

gw pharmaceuticals plc (GWP) Details

GW Pharmaceuticals plc, a biopharmaceutical company, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines. It operates in three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of multiple sclerosis symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company’s product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. It has a strategic alliance with Otsuka Pharmaceutical Co., Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.

320 Employees
Last Reported Date: 05/11/15
Founded in 1998

gw pharmaceuticals plc (GWP) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 567.8K GBP
Founder, Executive Chairman and Chairman of N...
Total Annual Compensation: 696.1K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 389.8K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 421.8K GBP
Chief Medical Officer and Executive Director
Total Annual Compensation: 475.3K GBP
Compensation as of Fiscal Year 2014.

gw pharmaceuticals plc (GWP) Key Developments

GW Pharmaceuticals plc Appoints Julian Gangolli to the Board of Directors

GW Pharmaceuticals plc announced that the company has appointed Julian Gangolli to the Board of Directors with immediate effect. This follows the announcement on 19 May 2015 of Mr. Gangolli's appointment to the newly created position of President, North America. Mr. Gangolli, was, from 2004 until April 2015, President of the North American Pharmaceutical division of Allergan Inc. As a Corporate Vice President and member of the Executive Committee, Allergan's most senior leadership team overseeing worldwide operations. Prior to Allergan, Mr. Gangolli was Vice President, Sales and Marketing at VIVUS Inc. where he established from inception a fully functioning commercial operation. Prior to VIVUS, Mr. Gangolli held roles at Syntex Pharmaceuticals Inc. and Ortho-Cilag Pharmaceuticals Ltd. in the UK. He grew up and was educated in the UK and is a U.S. citizen.

GW Pharmaceuticals plc Initiates Second Phase 3 Pivotal Study of Epidiolex in Lennox-Gastaut Syndrome

GW Pharmaceuticals plc announced that it has commenced the second of two Phase 3 clinical trials of Epidiolex for the treatment of Lennox-Gastaut syndrome, a rare and severe form of childhood-onset epilepsy. During 2014, GW received Orphan Drug Designation from the U.S. Food and Drug Administration for Epidiolex for the treatment of LGS. GW anticipates that top-line data from this trial will be available in the first quarter of 2016. The LGS Phase 3 pivotal trial program comprises two studies, both of which comprise a randomized, double-blind, 14-week comparison of Epidiolex versus placebo. The treatment period consists of a two-week titration period followed by a 12-week maintenance period. One Phase 3 trial has two arms of 50 patients; 20mg/kg and placebo, whereas the second study also includes a low dose treatment arm, and therefore includes a total of 150 patients. The primary measure of efficacy in both trials will be the comparison between Epidiolex and placebo in the percentage change from baseline in number of drop seizures. Several additional efficacy and safety secondary outcome measures will be analysed.

GW Pharmaceuticals plc Appoints Julian Gangolli as President, North America; to Expand its UK Manufacturing and R&D Operations

GW Pharmaceuticals plc announced that the company has appointed Julian Gangolli as President, North America and is also relocating its Chief Executive Officer, Justin Gover, to the United States. Mr. Gangolli was, from 2004 until April 2015, President of the North American Pharmaceutical division of Allergan Inc, with responsibility for a 1,400-person integrated commercial operation with sales exceeding $3.8 billion in 2014. Mr. Gangolli was an integral part of the executive management team that transformed Allergan into one of the leading specialty pharmaceutical companies in the U.S. Mr. Gangolli will join the company in June and is expected to be appointed to the company's board of directors. As President, North America Pharmaceuticals, Mr. Gangolli's responsibilities represented over 50% of Allergan's revenue, 60% of its profit, and over 60% of its year-on-year profit growth. He was responsible for four business units supporting each of the specialty areas of Ophthalmology/Optometry (Eye Care), Neurosciences, Urology and Medical Dermatology for the U.S. and Canada, each of which are considered category leaders in their respective therapeutic areas. In addition to his commercial responsibilities, Mr. Gangolli had responsibility for strategic planning, business development, research and product development planning for the North American division. Prior to his role as President, North America, Mr. Gangolli was Senior Vice President, U.S. Eye Care, at Allergan from 1998 to 2004. The company is also continuing to expand its UK manufacturing and R&D operations in preparation for future commercialization as well as pipeline development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GWP:LN 606.00 GBp +4.00

GWP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cannabis Science Inc $0.02 USD -0.0006
Medical Marijuana Inc $0.05 USD -0.0022
PharmaCyte Biotech Inc $0.12 USD -0.0007
View Industry Companies
 

Industry Analysis

GWP

Industry Average

Valuation GWP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 51.5x
Price/Book 10.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 56.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GW PHARMACEUTICALS PLC, please visit www.gwpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.